Corvus Pharmaceuticals, Inc. (CRVS) 8-K Current Report — March 13, 2026
Filed: March 13, 2026
Health Care
Pharmaceutical PreparationsCorvus Pharmaceuticals, Inc. (CRVS) 8-K current report filed with SEC EDGAR on March 13, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
Corvus Pharmaceuticals, Inc. 8-K Mar 13, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • ATM facility doubled to $200M from $100M — Jefferies acting as sales agent at up to 3.0% commission on gross sales
- • Zero shares sold under original $100M agreement (Aug 2024), so full $200M capacity is available
Other Corvus Pharmaceuticals, Inc. 8-K Filings
Get deeper insights on Corvus Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.